Manufacturers of biopharmaceuticals for respiratory disorders are faced with a tough task when deciding upon the most suitable method of delivering their products. Due to the high molecular weight and high polarity of such compounds, injection is often the only suitable technique. Confronted with this problem, Dr Igor Gonda from Genentech, US, described how a stable formulation of recombinant human deoxyribonuclease [rhDNase; Pulmozyme®] was developed. Details of the approach were presented at an IIR Ltd meeting ‘Successfully Exploiting the Commercial Potential of Drug Delivery Systems for New and Existing Therapeutics’ [London, UK; January 1995].